Should the government get a cut of the profits from pricey drugs birthed as research projects inside government-funded labs? That question has been sparking a debate, thanks in large part to newly elected U.S. Rep. Alexandria Ocasio-Cortez (D-N.Y.).

At a congressional hearing this week in Washington, Ocasio-Cortez expressed the view that the National Institutes of Health act like an early investor in the development of drugs. But when those drugs later become privatized, the government receives no return on its investment. Her view prompted pushback from some in the drug industry, including Derek Lowe. A medicinal chemist for 30 years, he currently works on drug discovery projects for a large pharmaceutical company in the Boston area.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy